We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (SART)

This study is currently recruiting participants.
Verified January 2016 by Wolfram Samlowski, Comprehensive Cancer Centers of Nevada
Sponsor:
ClinicalTrials.gov Identifier:
NCT01565837
First Posted: March 29, 2012
Last Update Posted: February 1, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Comprehensive Cancer Centers of Nevada
Information provided by (Responsible Party):
Wolfram Samlowski, Comprehensive Cancer Centers of Nevada
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2017
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)